Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2023-03-24 Report Publication Anno…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Ultimovacs ASA: Annual Report 2022
Report Publication Announcement Classification · 100% confidence The document explicitly states 'Ultimovacs ASA: Annual Report 2022' in the title and body. However, the text is very short (1321 characters) and primarily serves to announce that the Board has approved the Annual Report and ESG Report for 2022, and that these reports are available as attachments or on the website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report is attached or published should be classified as a Report Publication Announcement (RPA), rather than the full report itself (10-K or AR). Since this document announces the publication of the Annual Report, RPA is the most appropriate classification.
2023-03-24 English
Ultimovacs to Present at Cowen Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement titled "Ultimovacs to Present at Cowen Healthcare Conference." It explicitly states that the CEO and CMO will present at a specific industry conference (Cowen Healthcare Conference) on a future date. This type of announcement, detailing participation in an external industry event rather than releasing mandatory financial results or statutory reports, is typically classified as a general investor relations update or a regulatory filing if no other specific category fits. Since it is an announcement about an upcoming presentation at a conference, it does not fit 10-K, ER, IR, or IP. It is not a management change (MANG), dividend (DIV), or share transaction (POS). Given its nature as a brief, non-financial-result-focused update intended for the market, and following the 'MENU VS MEAL' rule (it's an announcement, not the presentation itself), the most appropriate general category is Regulatory Filings (RNS), as it is a non-standard announcement published to the stock exchange.
2023-02-27 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation Classification · 99% confidence The document is explicitly titled "Fourth Quarter 2022 Results" and contains detailed financial tables comparing Q4-22 results with Q4-21, along with operational updates on clinical trials and expected financial runway. This structure—quarterly financial highlights, operational review, and forward-looking statements—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on the 'Results' and provides key financial figures (MNOK 72 vs MNOK 51 for Q4), it fits the definition of an Earnings Release (ER) which is the initial announcement of periodical financial results. It is not a full Annual Report (10-K) as it covers only Q4/FY 2022, nor is it a Call Transcript (CT) or a formal Investor Presentation (IP), although it is presented as a 'presentation'. Given the focus on 'Q4 2022 Results' and key financial metrics, ER is the most appropriate classification over IR, which is typically more comprehensive like a half-year report.
2023-02-16 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the fourth quarter of 2022 (Q4 2022) for Ultimovacs. It includes detailed operational updates, clinical trial progress, a CEO statement, and a financial summary table containing income statement and cash flow data. Since it covers a period shorter than a full fiscal year and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. Q4 2022
2023-02-16 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Classification · 100% confidence The document is titled "Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update". It explicitly details financial results for Q4 2022 (e.g., operating expenses, net loss, cash flow) and provides a comprehensive update on clinical trial progress, which is characteristic of a periodic financial report. Since it covers a period shorter than a full year (Q4 2022), it fits the definition of an Interim/Quarterly Report (IR). Although it mentions that the full quarterly report and presentation will be published later that day, the content provided here summarizes the key financial outcomes and operational highlights, making it function as the primary release of those results, which aligns best with the comprehensive nature of an IR, rather than just an announcement of publication (RPA). Given the detailed financial figures and operational review, IR is the most appropriate classification over ER (which is usually just highlights) or RPA (which is usually much shorter and only announces the availability of the main document). Q4 2022
2023-02-16 English
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1202 characters) from Ultimovacs ASA inviting stakeholders to a webcast presentation for their fourth quarter 2022 results scheduled for February 16, 2023. It explicitly states that the 'report and presentation will be available on the company website from 08:00 CET the same day.' This structure—an invitation/notice about an upcoming release of financial results—fits the definition of a Report Publication Announcement (RPA), as it announces the publication of the results/presentation rather than containing the full results themselves (which would be an ER or IR).
2023-02-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.